Navigation Links
PharmAthene Reports Third Quarter 2009 Financial and Operational Results
Date:11/12/2009

es, and with preparing and submitting various bids and proposals, along with increased non-cash, stock-based compensation costs for the nine month period.

For the third quarter of 2009, PharmAthene's net loss was $14.0 million, or $0.50 per share, compared to $4.3 million or $0.20 per share, in the same period of 2008. For the nine months ended September 30, 2009, the Company's net loss was $26.6 million, or $0.97 per share, compared to $31.2 million, or $1.41 per share in the same period of 2008.

On July 28, 2009, PharmAthene issued 2-year, 10% unsecured senior convertible notes and common stock purchase warrants ("New Convertible Notes and Warrants") in a private placement in the aggregate principal amount of approximately $19.3 million. This private placement included the issuance of $10.5 million in New Convertible Notes and Warrants to new investors for cash and $8.8 million in New Convertible Notes and Warrants in exchange for 8% senior unsecured convertible notes due August 3, 2009 ("Old Notes") and accrued interest in the same amount. The New Convertible Notes issued in exchange for the Old Notes were accounted for as an early extinguishment of debt, resulting in a non-cash loss on extinguishment of debt of approximately $4.7 million. The proceeds from the sale of the New Convertible Notes and Warrants were used to repay $5.5 million of our Old Notes that were not exchanged for the New Convertible Notes and Warrants and to repay all outstanding amounts and fees under our existing credit facility.

As of September 30, 2009, available cash, cash equivalents and short term investments were $11.6 million. In addition, billed and unbilled accounts and other receivables were $18.7 million at September 30, 2009. The Company estimates that at its currently projected rate of net cash consumption, the existing sources of cash and cash receipts from contract receivables will be sufficient to fund operations through the end of 2010.'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013 iLuv Creative Technology, the premier ... the mobile lifestyle, announces they are now shipping MultiCharger-X, ... multiple iPad devices efficiently. Winner of the 2013 internationally ... Design award, MultiCharger-X is revolutionizing the way businesses, schools, ... deployed. , MultiCharger-X (iAD910) combines the ...
(Date:5/22/2013)...  Empire Genomics announced today it has acquired ... genomic biomarker from Cornell University for use in ... in diagnosing and determining treatment for patients with ... prostate cancer (NEPC) is a lethal variant of ... but more commonly arises after hormonal therapy for ...
(Date:5/22/2013)... BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is ... Conference, May 30, in New York, NY ... CPA, Chief Financial Officer of Cleveland BioLabs, will present the ... p.m. Eastern Time.  A live and archived webcast of the ... the Cleveland BioLabs website at www.cbiolabs.com . ...
(Date:5/22/2013)... May 22, 2013 Alton Housing Authority was ... 15, 2013 said that their presence has already caused ... bug sufferers avoid such big spending, My Cleaning Products shared ... , It was said in the report that to clear ... related. Apart from that, its employees also attended a mandatory ...
Breaking Biology Technology:iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2
... Physicians and Researchers Specializing in Ear Diseases to ... Otonomy Inc. today introduced its scientific advisory ... in diseases and disorders of the ear. The ... Rick Friedman, M.D., Ph.D.; Jeffrey Harris, M.D., Ph.D.; ...
... care in January, the industry seems to have taken a deep breath and ... care job cuts that were announced were mostly due to the overall economic ... ... be irresponsible to say the worst is past for health care, it does ...
... their use of energy and materials, according to a ... major manufacturing processes. , Overall, new manufacturing systems are ... of energy, per pound of output, than more traditional ... up orders of magnitude more energy than making manhole ...
Cached Biology Technology:Otonomy Introduces Scientific Advisory Board 2Otonomy Introduces Scientific Advisory Board 3Otonomy Introduces Scientific Advisory Board 4Otonomy Introduces Scientific Advisory Board 5The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 3MIT: 'Alarming' use of energy in modern manufacturing methods 2MIT: 'Alarming' use of energy in modern manufacturing methods 3
(Date:5/22/2013)... to improve durability in fuel cell powered buses, ... discovered links between electrode degradation processes and bus ... effects of electrode degradation stressors in the operating ... , The findings of the study, led by ... in a long-term study at Burnaby-based Ballard Power ...
(Date:5/22/2013)... streamlined approach to genetic engineering drastically reduces the ... into bacteria, the workhorses of biotechnology, scientists are ... Biology , the method paves the way for ... development, environmental cleanup and other activities. , Keith ... a piece of the genetic material DNA into ...
(Date:5/22/2013)... UCLA life scientists provide important new details on how ... published online May 21 in the Journal of ... to making accurate predictions and informing policymakers of how ... , "There is a growing recognition among ... with one another, and that this is going to ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... -- A novel antibacterial protein targeted against E. coli ... serious food-borne bacterial infections, as demonstrated in a study ... and Chemotherapy . Results in an animal model of ... administered protein, developed by AvidBiotics, Inc., could prevent or ...
... Caenorhabditis are usually thought of as soil nematodes, ... Caenorhabditis elegans has provided a wealth of ... worms have been at the forefront of three Nobel ... all other known Caenorhabditis species are as distantly related ...
... effect on release of CO2 from peat far greater than ... into the atmosphere than has previously been realised. Much ... increased frequency and severity of drought as a result of ... vast stores of carbon dioxide (CO2) into the atmosphere. It,s ...
Cached Biology News:Targeted antibacterial proteins may offer antibiotic alternative 2Targeted antibacterial proteins may offer antibiotic alternative 3Molecular barcodes - identification of 16 new species of Caenorhabditis 2Climate change effect on release of CO2 from peat far greater than assumed 2
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... suitable for a wide range of molecular ... Pulsed Field Gel Electrophoresis (PFGE). Due to ... Multi ABgarose can effectively separate large DNA ... turn means reduced band diffusion, a problem ...
... molecular screening, low melting point agarose where ... is recommended for separation of nucleic acids ... PCR products. Micro ABgarose is also suited ... for blotting techniques. At a 3% concentration, ...
Biology Products: